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Virus envelope proteins determine receptor utilization and host range. The choice of receptor not only permits specific targeting of cells that
express it, but also directs the virus into specific endosomal trafficking pathways. Disrupting trafficking can result in loss of virus infectivity due to
redirection of virions to non-productive pathways. Identification of the pathway or pathways used by a virus is, thus, important in understanding
virus pathogenesis mechanisms and for developing new treatment strategies. Most of our understanding of alphavirus entry has focused on the Old
World alphaviruses, such as Sindbis and Semliki Forest virus. In comparison, very little is known about the entry route taken by more pathogenic
New World alphaviruses. Here, we use a novel contents mixing assay to identify the cellular requirements for entry of a New World alphavirus,
Venezuelan equine encephalitis virus (VEEV). Expression of dominant negative forms of key endosomal trafficking genes shows that VEEV must
access clathrin-dependent endocytic vesicles for membrane fusion to occur. Unexpectedly, the exit point is different from Old World alphaviruses
that leave from early endosomes. Instead, VEEValso requires functional late endosomes. Furthermore, unlike the Old World viruses, VEEVentry
is insensitive to cholesterol sequestration from cell membranes and may reflect a need to access an endocytic compartment that lacks cholesterol.
This indicates fundamental differences in the entry route taken by VEEV compared to Old World alphaviruses.
© 2005 Elsevier Inc. All rights reserved.Keywords: Venezuelan equine encephalitis virus; Virus entry; Membrane fusion; Endocytosis; Late endosome; Cholesterol; AlphavirusIntroduction
VEEV is endemic to regions of South America, but is
normally maintained in a silent enzootic cycle between Culex
mosquitoes and rodents. However, sporadic outbreaks involv-
ing hundreds of thousands of people have been reported since
1938. These result from transmission of the virus to equines
(horses, mules and donkeys) where it becomes efficiently
amplified. Human infections via Aedes mosquitoes then follow
(Weaver et al., 1996). Fatality in equines ranges from 38 to 80%
and represents a heavy burden on the agricultural industry. Most
humans succumb to a debilitating, acute febrile illness with
rapid onset, lasting up to 2 weeks, and results in severe
leucopenia, increasing susceptibility to secondary infection.
Children and pregnant women are at greater risk, with 1 in 25Abbreviations: VEEV, Venezuelan equine encephalitis virus; MLV, murine
leukemia virus; env, envelope protein.
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for life. In 1971, VEEV crossed over the Mexican border into
Texas, resulting in the deaths of 200,000 equines in Mexico and
Texas before the disease was controlled by massive veterinary
vaccination. With both mosquito vectors resident in North
America, increased insecticide resistance in mosquitoes (Pie-
trantonio et al., 2000) and increases in population density
(Schmidt, 2000), similar outbreaks are inevitable. Presently,
there is no FDA-certified vaccine for VEEV, and the attenuated
military vaccine has poor efficacy (Russell, 1999). Drugs such
as Ribavirin, which are useful against other RNA viruses, are
ineffective against VEEV (Canonico et al., 1984). Our
knowledge of the mechanisms of pathogenesis for VEEV is
extremely limited, and a more detailed understanding of the
host–virus interaction will be required for the development of
new therapeutics and diagnostic tools.
VEEV is a member of the family Togaviridae, genus
alphavirus. It has a similar structure and genomic organization
to those of other alphaviruses, including Sindbis (SINV), Ross
River, Eastern Equine Encephalitis and Semliki Forest virus
Fig. 1. Construct design and env-luc expression. (A) Recombinant env gene was
made in the mammalian expression vector pCDNA3 (Invitrogen). The single
ORF encoded the env of VEEV from E3 through E1 as previously reported
(Kolokoltsov et al., 2005), except the termination codon was removed and fused
to a gene encoding three copies of the HA epitope (HA) which, in turn, was
connected to the firefly luciferase gene. (B) Expression of the recombinant
VEEVenv gene was examined when makingMLV particles by a Western blot of
lysates of transfected cells (left) and pelleted virus (right). Cells were transfected
to make MLV particles (as described in Materials and methods) pseudotyped
with env from eco-MLV (lanes 1 and 4), VEEVenv with HA-tag (lanes 2 and 5)
or the VEEV env-luc construct (lanes 3 and 6). Open and solid arrowheads
indicate predicted size of VEEV HA-tagged E1 protein and E1-luc proteins,
respectively.
334 A.A. Kolokoltsov et al. / Virology 347 (2006) 333–342(SFV). Virus particles are 60–70 nm in diameter, consisting of
an 11.5-kb RNA genome encapsulated in an icosahedral capsid
and coated by a lipid membrane derived from the cell at the time
of budding. Embedded in this membrane and non-covalently
associated with the underlying capsid are the envelope proteins
(envs) E2 and E1 (Paredes et al., 2001). These structural proteins
are made as a single polyprotein together with capsid which
cleaves itself from the envs soon after synthesis. The envs are
cleaved apart by furin and from their signal peptides (E3 and 6K)
by host signal peptidases (Strauss and Strauss, 1994).
The envs define the majority of cell tropism for enveloped
viruses by determining receptor specificity and, thereby, the
entry route into the cell. For the pH-dependent alphaviruses,
trafficking to endosomes is also controlled by the envs, where a
necessary drop in endosomal pH induces conformational
changes in the envelope protein that promote fusion of the
virus and cell membranes. By expressing dominant negative
genes that inhibit endosome formation, Influenza A was found
to require late endosomes for infection of cells, whereas
vesicular stomatitis and SFV (an Old World alphavirus)
required early endosomes that are less acidic than late
endosomes (Sieczkarski and Whittaker, 2003). The virus thus
regulates its endocytic release by setting the pH-threshold at
which the env undergoes its conformational change. Mutations
in envs that alter this threshold severely abrogate virus
infectivity (Gething et al., 1986), indicating that the release
point is crucial in establishing infection.
TheOldWorld alphaviruses, such as SFVand SINV, dominate
our knowledge of the alphavirus infection cycle, whereas little is
known about the highly virulent NewWorld alphaviruses such as
VEEV, especially pertaining to entry. Since many examples exist
of closely related viruses adopting distinct entry pathways, for
example picornaviruses enter cells by clathrin-mediated endo-
cytosis or caveolae and lipid rafts (Pietiainen et al., 2004), it is
important to determine if similar trends exist for the alphaviruses.
Indeed, it has been suggested that residue differences between the
envs of VEEV and SFV may define dependence on cholesterol
for membrane fusion in model membranes and insect cells
depleted of cholesterol (Lu et al., 1999). However, cholesterol
dependence has never been tested in mammalian cells. Here, we
demonstrate the usefulness of a novel contents mixing assay
originally described for murine leukemia viruses (Kolokoltsov
and Davey, 2004) to study the entry of VEEV-env pseudotyped
viruses in real time and at low MOI. Using dominant negative
mutants and drug inhibitors of the endocytic trafficking pathway,
we directly show that VEEVenters cells from the late endosomes
and entry resists cholesterol depletion differing from SFV which
exits from early endosomes and is more dependent on free
membrane cholesterol. This indicates an entry mechanism that is
distinct from the Old World alphaviruses.
Results
Application of a novel contents mixing assay to alphaviruses
Cellular events that lead to enveloped virus entry are poorly
understood, principally due to a lack of quantitative andsensitive assay systems that can measure entry in real time. For
alphaviruses, work has focused on the Old World alphaviruses,
SFVand SINVas each grows to high titer and is non-pathogenic
to humans. For both, infection of mammalian cells can be
triggered by a drop in pH. This has been shown using lipid
mixing assays, which measure the dispersion of fluorescently
labeled probes from virus membranes into cell or artificial target
membranes, upon fusion (Smit et al., 1999; White and Helenius,
1980). However, these assays require large amounts of purified
virus making them difficult to perform with highly virulent
viruses, such as VEEV. Previously, we reported a new entry
assay for eco-MLV (Kolokoltsov and Davey, 2004) that allowed
accurate measurement of virus entry. Here, we demonstrate that
this assay can be adapted to alphaviruses and used to study
VEEV entry into mammalian cells.
The basis of the entry assay is the encapsulation of luciferase
enzyme directly into the virus particle. Only when virus–cell
membrane fusion takes place can the enzyme access its
substrates and generate a signal. Recently, we reported the
production and characterization of high-titer, VEEV env-
pseudotyped MLV (Kolokoltsov et al., 2005), and demonstrated
that these particles enter cells in a VEEV env-dependent
manner. Epitopes normally presented on wild-type envs were
also detected on particles and neutralized these particles
identically to wild-type virus. These pseudotypes are generally
accepted to adopt the entry mechanism and pathway of the env
donor but importantly do not replicate and provide the
opportunity to study the entry of dangerous viruses in low
level containment (Sharkey et al., 2001; Simmons et al., 2003).
We adapted the VEEV envs to accept the luciferase enzyme
as for the eco-MLVenv-based system. For this, we modified the
E1 protein of VEEV at the c-terminus to make a fusion with
luciferase (Fig. 1A). An extended linker peptide using 3-copies
Fig. 3. Virus entry kinetics. Viruses containing luciferase were concentrated and
applied to cells at an MOI of 10 for 1 min at 37 °C. Excess virus was then
washed free of cells by two washes and pelleting cells with remaining bound
virus (b5% of innoculum) for 1 min at 400 × g. The cells were then resuspended
in DMEM and incubated at 37 °C. At times indicated, samples of 105 cells were
taken and luciferase activity was measured (as described in Materials and
methods). The entry of MLV particles pseudotyped with envs of VEEV, eco-
MLV and VSV + eco-MLV was analyzed.
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produce virus-associated luciferase (Fig. 2). Furthermore, the
HA-tag also provided a simple way to detect the E1 protein by
Western blot (Fig. 1B, open arrowhead). The E1-luciferase
fusion protein was evident as an approximately 100-kDa band
on Western blots of cells (lane 3) and virus particles (lane 6,
solid arrowhead).
Virus particles were then characterized on continuous
sucrose gradients. Filtered culture supernatants were applied
to gradients, and fractions were collected. Virus titer, luciferase
activity after lysis and E1 reactivity by Western blot analysis
were measured. For each measurement, activity peaked in
fraction 4, corresponding to approximately 40% sucrose (Fig.
2). In our previous work, we used the ratio of luciferase signal
from lysed versus unlysed particles to gauge signal to noise.
From previous work, a ratio of N5 indicated that particles were
intact and would give a good measure of entry after membrane
fusion. Our VEEV construct gave a ratio of N10. Together with
the sucrose gradient data, this finding strongly indicated that the
VEEV-pseudotyped particles were intact, infectious and likely
to function well in an entry assay.
The particles were then tested in an entry assay. A major
advantage using pseudotyped virus is that the entry mechanism
of each virus can be evaluated and directly compared to other
particles where only the origin of the env has been changed.
Here, we used eco-MLV and VSV env particles as controls.
VSV enters cells through clathrin-mediated endocytosis while
eco-MLV is thought to enter at the cell surface. Cells were
incubated with virus-containing luciferase for times up to 2 h at
an MOI of 0.5. VEEV-env-luc, eco-MLV env-luc and VSV-
G + eco-MLV env-luc-coated particles were used. For each, a
signal was generated that increased over time (not shown). To
obtain an accurate determination of entry kinetics, we
performed a rapid-binding entry experiment. Virus was
incubated for 1 min with cells, after which unbound particles
were washed free by two rapid washes in DMEM. Cells and
bound virus were then incubated at 37 °C for up to 1 h, samples
were collected and luciferase activity measured. Eco-MLVenv-Fig. 2. Analysis of luciferase-containing virus particles. A continuous sucrose
gradient (0–60% w/v) was used to separate particles and fractions were taken.
Fractions were tested for the E1-HA-luciferase fusion protein by Western blot
and probing with an anti-HA monoclonal antibody (12CA5, Roche) at 1:2000
dilution. The secondary antibody was anti-mouse IgG-horseradish peroxidase
conjugate at 1:2000. Fractions were also assayed for virus titer using a β-galac-
tosidase reporter assay, and luciferase activity was measured after lysis of
particles in 1% Triton X-100.coated particles were assayed on 293 cells expressing a
recombinant form of the eco-MLV receptor. Others were
assayed on 293 cells. Since we are measuring entry kinetics
in real time, we have found that small changes in incubation
conditions can greatly affect the measurements. In our previous
work, we reported that eco-MLV entered with a half-time of 40
min (Kolokoltsov and Davey, 2004). We have since observed
that eco-MLV is very temperature sensitive and use of an air
incubator gave poor heat transfer to the cells. Using a waterbath
gave a more accurate half-time of entry of 20 min for eco-MLV.
The entry of VSV-G- and VEEVenv-bearing particles was more
rapid, with half-times of 15 and 10 min, respectively (Fig. 3)
and not as temperature-dependent (data not shown). These
kinetics are consistent with a rapid entry pathway for VEEV,
possibly that of clathrin-mediated endocytosis.
To further test the specificity of the entry signal, virus was
preincubated with VEEV-reactive antibodies before application
to cells. The signal from the VEEV particles was reduced by
N80%, whereas VSV particles were unaffected (Fig. 4, upper).
This indicated that the particles entered cells by a VEEV env-
mediated mechanism.
Old World alphaviruses enter cells through a pH-dependent
mechanism. To determine if VEEV entry uses this mechanism,
cells were treated with inhibitors of endocytic acidification and
then luciferase entry assays were performed. Eco-MLV (a pH-
independent virus) env-bearing particles served as a control for
cell viability (Kolokoltsov and Davey, 2004). The inhibitors
bafilomycin, ammonium chloride, chloroquine and monensin
were used. Each effectively blocked the entry signal for VSV (a
pH-dependent virus) env-bearing particles and decreased the
VEEV entry signal similarly. In contrast, the eco-MLV was
unaffected indicating that cells were competent for mediating
virus entry and that the kinetics of the luciferase-based
measurement had not been altered (Fig. 4, lower). Together,
these data indicated that VEEV particles enter cells by a pH-
dependent mechanism, and that the luciferase-entry-assay
reflected the entry pathway used by infectious virus validating
Fig. 5. FACS analysis of expression of DN genes following transfection or
delivery by lentiviral vectors. (A) Cells were transfected using calcium
phosphate-mediated transfection with plasmids encoding the indicated GFP-
tagged constructs. Expression levels were then monitored by FACS analysis.
20,000 events were counted for each sample. Expression levels were seen at a
low (majority) and high level. (B) Cells were transduced with lentivirus
expression vectors encoding the indicated GFP-tagged constructs at anMOI of 5.
Expression profiles were then determined by FACS analysis. As compared to the
calcium-mediated transfection, a more uniform profile of expressionwas seen for
each. Two independent experiments are shown for each.
Fig. 4. Neutralization of VEEV particles by virus-specific antibodies and effects
of inhibitors of endosomal acidification. For antibody neutralization (upper
panel), virus was incubated with the indicated antibody for 1 h at a dilution of
1:200. Cells were then added and incubated for 1 h at 37 °C and then pelleted by
centrifugation at 400 × g, and luciferase activity was measured (as described in
Materials and methods). Antibody 411 is preimmune serum from the rabbit used
to make VEEV-specific antisera #711. 701 is a second immune rabbit serum
from ATCC. Rab1 was a rabbit hyperimmune antisera against VEEV provided
by Dr. Weaver, UTMB. A VSV-G pseudotyped MLV was used to detect non-
specific neutralization of virus. The effect of inhibitors of endosomal
acidification was also tested (lower panel). Each inhibitor (indicated) was incu-
bated with cells for 1 h prior to addition of virus (MOI of 0.1) and throughout the
30 min incubation with virus. Results are the average of 3 independent
experiments, and data were normalized to signals obtained from untreated or
solvent controls. Inhibitors used were Bafilomycin A1 (50 nM, final
concentrations given), Ammonium chloride (NH4Cl, 20 mM), chloroquine
(100 μM) and Monensin (1 μM).
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mechanism of VEEV.
Little is known about the entry route of New World viruses,
such as VEEV. As shown above, an endocytic pH-drop is an
important step in VEEVentry. However, a number of endocytic
pathways have been identified that become acidified, and many
inhibitors do not discriminate between these (Johannes and
Lamaze, 2002). In addition, drugs such as Bafilomycin can
indirectly affect the trafficking of endocytic vesicles (van Weert
et al., 1995). Ectopic expression of dominant negative (DN)
mutant forms of genes important in endocytic trafficking
provides an alternative means to block key endocytic steps. We
chose DN forms of Eps15, Rab5 and Rab7 as each blocks a
specific step in endocytic trafficking and tested each in the entry
assay for its impact on VEEVentry. The mutant form of Eps15,
EΔ95/295, has a 200-amino acid deletion that prevents
association with AP2, a key mediator of clathrin-mediated
endocytosis and inhibits this pathway. Rab5 S34N and Rab7T22N block endocytic vesicle trafficking to the early and late
endosomes, respectively (Feng et al., 2001). Rab5 Q79L is a
constitutively active form of Rab5 and causes accumulation of
early endosomes (Roberts et al., 1999). A major drawback in
using these genes is they need to be introduced into cells by
transfection using expression constructs. We found that this
resulted in highly variable expression, complicating any
quantitative measurement (Fig. 5A, right). To overcome this
obstacle, each gene was subcloned into a lentiviral packaging
plasmid and used to produce lentiviruses. The use of lentivirus
vectors is advantageous, as the transgene is permanently
integrated into the cell chromosome, and gene transcription is
driven by normal cellular transcription machinery with no viral
genes present. Additionally, the expression levels can be
controlled by the MOI of lentivirus infection. Each DN gene,
tagged with GFP, was introduced into 293 cells using lentivirus
vectors and expression profiles analyzed by FACS (Fig. 5B). At
an MOI of 5, N95% of the cells expressed the transgene within
5-fold of the mean, which was 100-fold above background
values defined by vector without insert. The exception was
EΔ95/295 that gave consistently low level expression.
However, as noted below, the gene product functioned well,
indicating that the low fluorescence signal may be due to high
protein turnover. Given the generally high efficiency of
transgene expression, the entry assay measurements should
337A.A. Kolokoltsov et al. / Virology 347 (2006) 333–342reflect the overall effect gene expression on the entire cell
population.
The effect of the clathrin-pathway blocking DN mutant of
Eps15, EΔ95/295, was examined first. As a control, the impact
of each trafficking gene mutant was monitored by observing
transferrin uptake, which occurs strictly through the clathrin-
mediated endocytosis. Cells were incubated with Alexafluor594-
transferrin and, after fixing, the distribution of the gene product
and the labeled transferrin was assessed by confocal microscopy
(Fig. 6A). In untreated cells, label was rapidly taken up into the
cytoplasm with punctuate staining (Fig. 6, control). However, in
cells infected with the EΔ95/295 encoding lentivirus, the
transgene product was weakly but evenly distributed throughout
the cytoplasm, while the labeled transferrin was found only on
the surface and within a small region near the nucleus. This
indicated that clathrin-mediated endocytosis had been effec-
tively inhibited. Entry was then measured for VEEV, VSV and
eco-MLV env-pseudotyped virus. VEEV and VSV behaved
similarly with N70% block in entry observed (Fig. 6B, open and
solid bars), while eco-MLV was not affected (Fig. 6B, stripedFig. 6. The effect of expressing mutant forms of proteins important in
endocytosis on virus entry. Mutant endocytic trafficking genes (GFP-tagged)
were delivered in lentivirus expression constructs, and after 36 h, the effect of
each on transferrin uptake (A) or virus entry (B) was determined. The effect of
ectopic expression of each gene on clathrin-mediated endocytosis was measured
by observing Alexafluor594-labeled transferrin (red) uptake by confocal
microscopy. Transgene products were localized by GFP fluorescence (green).
Vector alone (carries blasticidin resistance marker) was used as a control (titered
by drug selection). Outlines of representative cells expressing the transgene are
drawn in with dashed lines. Nuclei were stained with DAPI (blue). For virus
entry assays, MLV pseudotyped with envs from VEEV, SFV, VSVor eco-MLV
and containing luciferase enzyme was made (as described in Materials and
methods). These viruses were incubated with cells for 1 h at 37 °C, and then
entry signals were determined by measuring luciferase activity. Data are an
average from 3 independent experiments and signals were normalized to that
from cells infected with the vector alone.bars). This confirmed that, like VSV, VEEV required clathrin-
mediated endocytosis for triggering of entry.
Clathrin-dependent vesicles are trafficked and fuse to early
and late endosomes, becoming progressively more acidic. We
next examined the role of early and late endosomes in triggering
VEEV entry. DN mutant forms of Rab5 (S34N) and Rab7
(T22N) were used. As for EΔ95/295, each was made as a fusion
protein with GFP to track expression (Fig. 6, upper). Transferrin
uptake was used to confirm the effectiveness of expression of
each mutant on clathrin-mediated endosomal trafficking.
Expression of wild-type Rab5 did not appear to inhibit uptake
of transferrin, but distinct overlapping of transferrin and
punctate Rab5-GFP signal was observed, as expected. Expres-
sion of the DN Rab5 and Rab7 genes resulted in disruption of
this pattern. Rab5 S34N resulted in weak transferrin staining
similar to that observed for EΔ95/295. Expression of Rab7
T22N resulted in transferrin collecting in vesicles, but each was
larger and less numerous than those seen with wild-type Rab5.
A similar effect was described when this mutant was over-
expressed in HeLa cells (Feng et al., 2001). The constitutively
active mutant, Rab5 Q79L, was the most profound, giving rise
to large transferrin-containing vesicles bounded by the GFP
fusion protein. These likely represent accumulation of endo-
cytic vesicles at the early-endosome stage of maturation that
remain coupled to the mutant Rab5 (Roberts et al., 1999). In
each case, these phenotypes indicated that the expression
vectors were driving adequate expression levels of each DN
gene to obtain the desired phenotype.
VEEVentry was then measured, with VSVand eco-MLVenv
pseudotypes used as controls. A pseudotype of SFV was
included to permit direct comparison of VEEVentry to entry of
Old World viruses. The SFV construct was modified for use
with the luciferase entry assay (Saeed et al., submitted for
publication). VSV and SFV have been reported to exit the
clathrin-mediated endocytic pathway at the early endosome,
while eco-MLV is thought to enter cells at the plasma
membrane. Since the only difference between each of the
pseudotyped viruses is the env presented on their surfaces,
differences in the entry kinetics are solely a function of the envs.
For each of the genes expressed, MLV entry remained
unaffected (Fig. 6, lower), confirming that the cells remained
susceptible to virus entry and that ectopic expression of the
mutant genes did not adversely affect the luciferase assay
measurements. In contrast, expression of EΔ95/295, Rab5
S34N and Rab5 Q79L reduced the entry of VEEV, SFV and
VSV to a similar extent, i.e., by 80–90%. The ability of Rab5
Q79L to inhibit virus entry to a similar extent likely reflects
virus being held in the accumulated early endosomes at a step
prior to reaching the required acidification for triggering
membrane fusion. Overexpression of wild-type Rab5 reduced
VEEVand SFVentry similarly, by 30%, but did not affect VSV
entry kinetics. The effect of ectopic expression of wild-type
Rab5 on VEEV and SFV may reflect increased trafficking of
virus into a non-productive Rab5-mediated pathway that is still
productive for VSV. VEEV and SFV behaved differently when
Rab7 T22N was expressed in cells. VEEVentry was reduced by
Rab7 T22N to a similar extent seen with DN Rab5 and EΔ95/
338 A.A. Kolokoltsov et al. / Virology 347 (2006) 333–342295. In contrast, SFVand VSVentry was reduced by only 20%.
Together, these data are consistent with an entry route by which
VEEV is endocytosed through clathrin-mediated endocytosis
but entry is triggered in the late endosome, being affected by
blocks that lead up to and including this step.
The finding that the VEEV exits from late endosomes
indicates that the entry mechanism of this virus may be different
from the Old World alphaviruses. Previous work has demon-
strated that SFV and SINV require cholesterol for efficient
membrane fusion in model membranes lacking cholesterol and
insect cells depleted of cholesterol. The residues responsible for
cholesterol dependence were identified by isolating mutants that
were less dependent on the presence of cholesterol (Lu et al.,
1999; Vashishtha et al., 1998). Interestingly, some of the residue
changes identified are already present in the E1 env of VEEV.
The prediction that VEEV may enter by a cholesterol-
independent mechanism may indicate a further fundamental
difference between the Old and New World alphavirus entry
pathways and indicate a need to access an endocytic
compartment where cholesterol is lacking. To test this, we
used nystatin to sequester cellular cholesterol. Similar treat-
ments of cells have been previously shown to block the
cholesterol-dependent entry of Ebola (Empig and Goldsmith,
2002). A modification of the entry assay permitted use of Ebola
env particles as a control for the entry assay (Saeed et al.,
submitted for publication). Cholesterol-dependent uptake of
labeled cholera toxin B-subunit was also used to control for
effective cholesterol depletion by disruption of its cholesterol-
dependent uptake into cells (Orlandi and Fishman, 1998). The
minimum dosage of nystatin that disrupted cholera-toxinFig. 7. VEEV entry is insensitive to cell membrane cholesterol sequestration.
(A) Human fibroblasts (HEK 293 cells) were treated with 60 μg/ml nystatin
for 1 h and then were stained with Alexa568-labeled cholera toxin subunit B
for 30 min. The uptake of cholera toxin is dependent on free membrane
cholesterol (Orlandi and Fishman, 1998) and the minimal dosage required to
inhibit uptake (staining present on the cell surface but little internal staining)
was used for virus entry assays. (B) For entry assays, pseudotyped particles
with envs of VEEV, SFV, VSV or Ebola were used. Virus entry was measured
in untreated (open bars) or cells treated with 60 μg/ml nystatin (solid bars) by
measuring luciferase activity after 1 h. Values were normalized to the vehicle
(DMSO) treated control. Averages of two independent experiments are given.subunit uptake without affecting long-term cell viability was
60 μg/ml. At this dosage, Ebola entry was blocked by N90%.
Entry of VSV and SFV was also affected significantly, being
inhibited by 55 and 65%, respectively (Fig. 7). This contrasted
to VEEV that showed marked resistance to nystatin treatment
and entry being impaired by only 20%. This indicates that
VEEV enters by a mechanism that is independent of free-
cholesterol, making it distinct from the Old World alphaviruses.
Discussion
Luciferase-based contents mixing assay for VEEV
In our previous work, we reported the development of a
novel contents mixing assay for measuring the fusion of virus
and cell membranes (Kolokoltsov and Davey, 2004). This was
based on the concept that luciferase encapsulated within the
viral envelope remains inactive until it is exposed by a virus–
cell membrane fusion event, and the luciferase substrates
(luciferin, ATP and oxygen) can access the enzyme. The assay
provides advantages over previous methods that require
fluorescent dye addition to viral and/or cell membranes,
detection of viral genetic material release and direct micro-
scopic detection of fusion events. The assay sensitively and
quantitatively measures events very early in the infection
process and provides real-time kinetic measurements of the
entry process. The VSV and VEEV entry kinetics that we have
obtained compare favorably with those obtained using conven-
tional fluorophore dequenching assays, with half times of 15
min for each used for VSV, SFV and SINV (Blumenthal et al.,
1987). Since an MOI of b1 was used in our experiments, as
compared to 10–100 for dequenching assays, this finding
indicates little virus cooperativity in alphavirus entry.
Our findings show that the assay can be used to follow the
entry of class II enveloped viruses. These viruses, which include
flaviviruses and alphaviruses, have envs with distinctly different
structures to the envs of class I viruses such as MLV for which
the assay was originally developed. The luciferase gene was
fused directly to the 3′ end of the VEEV E1 gene, likely placing
the enzyme into the lumen of the virus particle. For this, a 30-
residue HA epitope peptide was required to obtain particles that
were initially impermeable to the luciferase substrates, as
indicated by the N10-fold increase in luciferase activity, upon
particle lysis in detergent. The added advantage of using the HA
epitope linker peptide was that we were able to detect E1
expression on Western blots by a commercially available anti-
HA monoclonal antibody. From this work, it seems that three
important factors contribute to successful adaptation of the
assay to new viruses. Firstly, the peptide tethering the luciferase
to the env may require customization. Secondly, constructs that
worked for both MLV (Kolokoltsov and Davey, 2004) and
VEEV showed the luciferase being partly cleaved off the env by
an unidentified protease(s). This, in turn, achieves two
outcomes: very little luciferase is actually taken into particles,
and the luciferase is free to separate from the viral membrane
after a fusion event. Thirdly, when making the viruses, it is
important to add the recombinant env-luc construct together
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1:5. Env-luc by itself results in defective particle formation, as
particles become permeable to luciferin. Taking these factors
into consideration, it should be possible to use this system to
measure entry for many other enveloped virus types. The assay
should readily be adapted to other established alphavirus
pseudotypes such as Ross River virus.
Mapping the entry pathway of VEEV
To date, many virus pseudotypes have been produced and in
each case these recapitulate the tropism of the envelope donor
virus. The VEEV pseudotypes used in this study were
thoroughly characterized in previous work by neutralizing
antibodies and entry inhibitors and shown to infect cells
identically to the parent virus (Kolokoltsov et al., 2005). The
pseudotypes provide an important advantage over wild-type
VEEV as they do not replicate and can be used safely in low
level containment. Here, we determined the entry kinetics of
the VEEV pseudotype and found that it closely reflected that
of the wild-type virus. Again, this supports the conclusion
that the pseudotype enters cells by a mechanism identical to
that of the parent virus.
Our measurements indicate that VEEV entry is very rapid,
reaching a plateau within 20 min after contact with cells. For all
of the viruses studied in our work, we have noticed that a lag of
approximately 10 min precedes the detection of an entry signal.
Since all of the kinetic analyses in this report were performed on
prewarmed cells and virus is prebound to cells, the lag must
reflect important postbinding steps necessary for entry. This
may represent the time required for trafficking into cellular
compartments where entry is triggered. Interestingly, eco-MLV
shares this sigmoidal entry kinetic. Given that MLV are
generally thought to penetrate at the cell surface and, therefore
not requiring endosomal trafficking (see below), the lag for
MLV suggests a need to either recruit multiple receptors or enter
a preendosomal membrane microdomain. The observation that
eco-MLV was unaffected by DN Rab5 and Eps15 mutant
expression is consistent with this conclusion.
We showed that VEEV enters cells by a pH-dependent
mechanism by treating cells with inhibitors of endosomal
acidification. Ammonium chloride and chloroquine function
as weak bases to buffer changes in endosomal pH (de Duve
et al., 1974). Monensin is an ionophore that decouples the
proton gradient in intracellular compartments (Mollenhauer
et al., 1990), while Bafilomycin A1 directly blocks the
endosomal ATPase-dependent proton-pump (van Weert et
al., 1995). Each was a potent inhibitor of entry for the
VEEV and VSV env pseudotypes. Both VSV and alpha-
viruses have been shown to have a strong pH-dependence,
which indicated that the assay was capable of measuring the
entry pathway of these viruses, which likely proceeded
through an endosomal pathway. In contrast, eco-MLV entry
was not inhibited. The MLV served as an important control
in this case, showing that the cells were competent for virus
entry and that the entry assay was not adversely affected by
any of the treatments.To more precisely determine the endosomal pathway
needed to trigger the VEEV entry mechanism and the point
at which entry was triggered, we used expression of
dominant negative forms of genes responsible for endocytic
trafficking. Since the assay measures virus entry for a
population of cells, it was important to obtain even and
robust expression in most cells. We used lentivirus
expression vectors, as they stably integrate the transgene
into cell chromosomes and drive high expression levels by
strong cis-acting promoters. By varying the MOI, we could
carefully control the level of transgene expression and
obtain consistent results.
Dominant negative gene expression indicated initially that
VEEV entry, like VSV, requires functional clathrin-mediated
endocytosis and early endosome formation. However, VEEV
differed from VSVand from its relative, SFV, as it also required
functional late endosomes, making VEEV more like Influenza
A than SFV and VSV. Further studies will be required to
determine if this difference is due to a lower pH-threshold at
which membrane fusion is triggered, as attained in the late
endosome or a dependence on secondary factors present in the
late endosome. A second difference was seen in the cholesterol
dependence of VEEV compared to SFV. Old World alphavirus
membrane fusion has been shown to be heavily dependent on
cholesterol and sphingolipids in the target membrane (Lu et al.,
1999; Phalen and Kielian, 1991). These studies were performed
using artificial membranes and insect cells depleted of
cholesterol using methyl-β-cyclodextrin. Similar studies have
not been performed with mammalian cells until now. Further-
more, mutant SFV have been isolated that are less cholesterol-
dependent. Amino acid substitutions responsible for cholesterol
insensitivity have been mapped to the E1 env protein
(Vashishtha et al., 1998). VEEV E1 already has residues that
were predicted to make the virus cholesterol insensitive. We
used nystatin treatment to sequester cholesterol and showed that
this treatment blocked entry of the cholesterol sensitive Ebola
virus (Empig and Goldsmith, 2002) and cholera toxin uptake,
which is also cholesterol-dependent (Orlandi and Fishman,
1998). SFVentry was also sensitive to cholesterol sequestration
albeit to a lesser extent than Ebola. In contrast, we found that
VEEV entry was relatively insensitive to treatment. Our
findings demonstrate that the observations made in model
membranes and insect cells on cholesterol dependence also
apply to mammalian cells. The difference in cholesterol
requirements may reflect differences in the membrane compo-
sition of vesicles from which the virus fuses and exits into the
cell cytoplasm. Indeed, the late endosomal compartment has
been shown to be depleted of membrane cholesterol while early
endosomes and recycling vesicles are enriched in cholesterol
(Kobayashi et al., 1998, 2002). The role of cholesterol in entry
of SFV may then reflect a need to exit from early endosomes
while VEEV has adapted to be less cholesterol-dependent due
to a need to exit from cholesterol-poor late endosomes. In
addition to pH, cholesterol may then provide a novel mecha-
nism for a virus to sense what step of maturation an endosomal
vesicle has reached so that it can exit at the optimal locale within
the cell for virus replication.
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drug screening assays
The development of the rapid entry assay for an alphavirus is
also useful for rapid diagnostic and drug screening assays.
Neutralization assays for VEEV are still used as the primary
method for detecting patient antibodies, as a marker of
concurrent or previous infection, and presently use infectious
virus or, more recently, reporter gene-expressing replicons.
Assays involving infectious virus require biocontainment level
3 facilities, and the CDC recommends that all personnel in these
facilities be vaccinated with the non-commercial military
vaccine TC-83. Virus and replicon assays yield results in 48–
72 and 6 h, respectively. However, it should be possible to use
luciferase-containing particles to yield a quantitative measure of
serum neutralization in 15 min after application of virus to cells.
Similarly, drug screens to identify factors inhibiting VEEVentry
could be rapidly implemented without the need for infectious
virus. The assay also provides information on drug action. Both
applications have advantages over current methods and will
help us to identify and treat disease resulting from VEEV
infection.
Materials and methods
Chemicals
Bafilomycin A1, chloroquine and monensin were from
Calbiochem (San Diego, CA). All other chemicals were Sigma
(St. Louis, MO) Ultragrade unless stated otherwise.
Antibodies
Polyclonal sera raised against VEEV were from ATCC.
These were sera 701 and 711 (ATCC #VR-1249AF and #VR-
1250AF). A third serum (rab1) was from an VEEV-infected
rabbit and was provided by Dr. Scott Weaver (UTMB, TX).
Non-VEEV reactive antiserum #411 was from a preimmunized
rabbit used to produce serum #711 (ATCC #VR-1250CAF).
Cell lines and cultivation
All media were supplemented with penicillin and strepto-
mycin. 293 HEK cells were used to titer virus and for entry
assays and grown in DMEM supplemented with 10% heat
inactivated fetal bovine serum (Gemini Bioproducts, CA).
293FT cells (Invitrogen, CA) were used to generate env
pseudotyped MLV and were grown in the same medium with
0.5 mg/ml of Geneticin (Invitrogen, CA).
Expression plasmid constructs
All plasmids were prepared using Qiagen kits (Valencia, CA)
or by cesium gradient centrifugation following standard
methods. A pCDNA3 (Invitrogen, CA) expression plasmid
containing the VEEV envelope proteins from E3 to E1 from
subtype IC strain 3908 was used to make VEEV envpseudotypes (Kolokoltsov et al., 2005). Similarly, a pCDNA3
expression plasmid containing the Semliki forest virus envelope
proteins was used for SFV pseudotype production and was
provided by Dr. D. Sanders (Indiana University Medical
School, IN) and is described elsewhere (Kahl et al., 2004).
Plasmids encoding VSV-G (pVSV-G; BD Biosciences, CA) and
ecotropic MLV strain Friend-57 (eco-MLV) env (pFR57) were
used to make VSVand eco-MLVenv pseudotypes, respectively.
These plasmids were described previously (Kolokoltsov et al.,
2005). An expression plasmid encoding Ebola Zaire strain GP
was obtained from Dr. P. Bates (U. Penn., PA). pGAG-POL
which encodes the MLV gag and polymerase was a gift of Dr. J.
Cunningham (Harvard Medical School, MA). Marker gene
encoding plasmids were pψ β-gal, pψ EGFP or pFB-luc
(Stratagene, CA). Each encoded β-galactosidase (β-gal),
enhanced green fluorescent protein (GFP) or firefly luciferase
(luc), respectively, under control of the MLV LTR and virus
packaging sequence.
Production of pseudotyped MLV
MLV particles bearing the env proteins of VEEV, VSV, SFV,
Ebola and eco-MLV were made according to our previous work
(Kolokoltsov et al., 2005). Briefly, 293FT cells (Invitrogen)
were transfected using calcium phosphate (Chen and Okayama,
1987) with pGAG-POL and either pψ β-gal, pψ EGFP or pFB-
luc and plasmids encoding envs. The VSV-G-encoding plasmid
was used at 1 μg per transfection to limit syncytia formation in
the producer cells. All others were used at 5 μg each. After
overnight incubation, the medium was replaced. When virus
production peaked after a total of 36 h, the supernatants were
collected and filtered through a 0.45-μm cellulose acetate filter.
The filtrate was used directly, or else virus was concentrated by
2 h centrifugation at 100,000 × g and the pellet used. In some
experiments, virus was purified by pelleting through 20% (w/v)
sucrose in 10 mM Na HEPES, pH 7.4.
Luciferase-based contents mixing assay
The basis of the rapid entry assay is to encapsulate luciferase
enzyme directly into intact virus particles. Our initial work with
the assay reported the construction of luciferase-containing
particles for VSV-G and MLV-env pseudotypes. For both, the
enzyme was taken into particles as a fusion to the c-terminus of
the eco-MLV env protein. To achieve this for VEEV, the
luciferase was fused to the c-terminus of the E1 envelope
protein. For this, PCR-based, site-directed mutagenesis was
used to replace the stop codon with an in-frame XhoI site. Three
copies of the HA epitope tag (Davey et al., 1997) were then
connected through this site, and the luciferase enzyme was then
connected in-frame through a SacI site at its 3′ end. The final
expression construct was assembled in pCDNA3 and named
pVEEV-env-luc, and the sequence of the finalized construct was
confirmed.
To make viruses containing luciferase, the expression
construct was transfected together with the other plasmids
used to make the env pseudotyped MLV. Typically, 1 μg of
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env-expressing vector. Viruses were treated as above for other
MLV pseudotypes. Entry assays were performed on 293 cells
and typically involved incubating virus-containing culture
supernatants with 105 cells for 1 h in a 37 °C waterbath at an
MOI of 1 or less. Cells were then pelleted and resuspended in
luciferase assay buffer (Promega, #E2510), after which light
emission was detected in a Turner biosystems model 20/20
luminometer at 10 s, 1 min and 2 min. Typically, signal rapidly
increased and reached a plateau after 1 min as luciferin entered
the cells. To ensure that luciferin permeated subcellular
compartments, cells were frozen in a dry-ice ethanol bath and
quickly thawed in a 37 °C waterbath. With this treatment, virus
remained intact (impermeable to luciferase substrates) but cells
became permeable to trypan blue dye.
Rapid-binding entry kinetic assay
For analysis of entry kinetics, the above method was
modified to pulse cells with virus for a short time, wash off
excess virus and then follow the entry of the bound virus. This
was done by briefly incubating cells with virus (typically 1 min)
at an MOI of 10 infectious particles per cell. During this time,
b5% of the virus bound and the excess was washed off by two 1
min washes in prewarmed DMEM. The cells and remaining
bound virus were incubated for times indicated, samples taken
and luciferase activity measured as above.
Determination of env-pseudotyped virus titer
293 cells were infected at a confluence of 20%, and virus was
titrated by serial 5-fold dilutions. Two days later, the medium
was removed and infected cells were stained for β-galactosidase
activity, or GFP expression was visualized by fluorescence
microscopy and colonies counted.
Use of inhibitors of endosomal acidification
Ammonium chloride and chloroquine were dissolved
directly in DMEM. Bafilomycin A1 was first dissolved in
DMSO at 50 μM, and monensin made as a 50 mM stock in
ethanol. Both were diluted in DMEM immediately before use.
For the entry assay, luciferase activity was measured after 0.5 to
1 h of incubation in the presence of the drug.
Use of dominant negative (DN) forms of endocytic trafficking
mediators
EΔ95/295 (provided by Dr. Benmerah at the Cochin
Institute, France) is a recombinant form of the Eps15 gene
and lacks the second and third N-terminal EH repeats required
for interaction with AP-2 and clathrin-coated pit formation.
Expression specifically inhibits clathrin-mediated endocytosis
in 293 HEK and other cell types (Benmerah et al., 1999). Rab5
and Rab7 are required for early and late endosome formation,
respectively. A DN recombinant form of Rab5, S34N, blocks
early endosome formation. The constitutively active mutant,Q79L, of Rab5 forces accumulation of early endosomes. Both
Rab5 S34N and Q79L encoding plasmids were provided by Dr.
P. Stahl at Washington University Medical School. Rab7 is
required for formation of late endosomes and expression of the
mutant form, T22N (Dr. Wandinger-Ness, UNM), blocks this
step (Feng et al., 2001). Each was tagged with GFP to follow
expression by epifluorescence microscopy. For each, a non-
replicating lentivirus expression vector was constructed to
permit permanent, efficient and uniform delivery by adjustment
of the multiplicity of infection (MOI) and overcame other
transfection artifacts.
Lentivirus expression vectors
For construction of lentivirus expression vectors, genes
encoding endocytic pathway factors were cloned into pLENTI6
(Invitrogen, CA) that had previously been modified to contain a
GFP gene. A common strategy was used: the plasmid vector
was cut with XhoI, and the site made blunt-ended using T4
DNA polymerase (NEB, MA) after which it was cut with SpeI.
Each insert was cut out from parent plasmids using NheI
(compatible overhang with SpeI) and HpaI (blunt ended) and
ligated into the pLENTI plasmid. VSV-G-pseudotyped lenti-
virus particles were made using the Virapower (Invitrogen, CA)
lentivirus expression system following the manufacturer's
instructions. This involved simultaneous transfection of
293FT cells with plasmids required for assembly and packaging
of the GFP-DN-fusion gene in a non-replication competent
retrovirus, a technique similar to that used for production of
MLV (see above). Virus-containing culture supernatant was
collected after 2 days (as for MLV), purified and concentrated
by centrifugation through a 20% (w/v) sucrose cushion
(100,000 × g) for 3 h at 18 °C, and titered on 293 cells by
counting colonies of cells expressing the GFP-fusion proteins.
Analysis of ectopic gene expression
To determine expression levels and number of cells
expressing each endocytic pathway gene, a portion of the
cells used for the entry assays and microscopy work was
analyzed by FACS using a FACSort flow cytometer equipped
with CellQuest Software (Becton Dickinson, CA). Typically,
20,000 events were recorded for each sample. Confocal
microscopy was performed on a Zeiss LSM 510 META in the
UTMB IDOIC imaging facility using cells cultivated on Labtek
8-well glass slides (Nalgene, NY) and fixed for 20 min in a fresh
solution of 4% paraformaldehyde in PBS. They were then
washed with PBS and covered with mounting medium
containing DAPI (Prolong gold antifade, Molecular Probes,
Invitrogen, CA). Transferrin uptake was used to demonstrate the
activity of the ectopically expressed mutant genes (Rabs and
Eps15) and as a measure of clathrin-mediated endocytic
trafficking. When performing transferrin uptake measurements,
cells were stained with 50 μg/ml of Alexafluor594-transferrin in
DMEM supplemented with 1% (w/v) BSA for 1 h at 37 °C.
Excess transferrin was removed with two DMEM washes, and
the cells were fixed with paraformaldehyde.
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Nystatin was dissolved in DMSO and cells were treated
with 60 μg/ml, which was the minimum dosage that
disrupted cholesterol toxin uptake, indicating that cholesterol
had been effectively sequestered. This was visualized by
staining of cells for 1 h with Alexa568-labeled cholera toxin
B (Molecular probes, CA). Labeling was visualized by
epifluorescence microscopy using a Leica DM IRB inverted
microscope fitted with a Optronics Magnafire camera. Virus
entry was monitored by luciferase activity as described
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